# Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic

> **NCT02972320** · PHASE2 · UNKNOWN · sponsor: **Yunpeng Liu** · enrollment: 60 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT02972320
- **Lead sponsor:** Yunpeng Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02972320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02972320, "Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02972320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*